GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amarantus Bioscience Holdings Inc (OTCPK:AMBS) » Definitions » Shares Outstanding (EOP)

Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) Shares Outstanding (EOP) : 21.18 Mil (As of Dec. 2015)


View and export this data going back to 2008. Start your Free Trial

What is Amarantus Bioscience Holdings Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Amarantus Bioscience Holdings's shares outstanding for the quarter that ended in Dec. 2015 was 21.18 Mil.

Amarantus Bioscience Holdings's quarterly shares outstanding increased from Dec. 2014 (5.61 Mil) to Dec. 2015 (21.18 Mil). It means Amarantus Bioscience Holdings issued new shares from Dec. 2014 to Dec. 2015 .

Amarantus Bioscience Holdings's annual shares outstanding increased from Dec. 2014 (5.61 Mil) to Dec. 2015 (21.18 Mil). It means Amarantus Bioscience Holdings issued new shares from Dec. 2014 to Dec. 2015 .


Amarantus Bioscience Holdings Shares Outstanding (EOP) Historical Data

The historical data trend for Amarantus Bioscience Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarantus Bioscience Holdings Shares Outstanding (EOP) Chart

Amarantus Bioscience Holdings Annual Data
Trend Oct08 Oct09 Oct10 Dec11 Dec12 Dec13 Dec14 Dec15
Shares Outstanding (EOP)
Get a 7-Day Free Trial 0.54 2.28 3.83 5.61 21.18

Amarantus Bioscience Holdings Semi-Annual Data
Oct08 Oct09 Oct10 Dec11 Dec12 Dec13 Dec14 Dec15
Shares Outstanding (EOP) Get a 7-Day Free Trial 0.54 2.28 3.83 5.61 21.18

Competitive Comparison of Amarantus Bioscience Holdings's Shares Outstanding (EOP)

For the Biotechnology subindustry, Amarantus Bioscience Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarantus Bioscience Holdings's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amarantus Bioscience Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Amarantus Bioscience Holdings's Shares Outstanding (EOP) falls into.



Amarantus Bioscience Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Amarantus Bioscience Holdings  (OTCPK:AMBS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Amarantus Bioscience Holdings Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Amarantus Bioscience Holdings's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
45 Wall Street, Suite 920, New York, NY, USA, 10005
Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.
Executives
Flanigan Conn other: Former Director 1601 BLAKE STREET, SUITE 310, DENVER CO 80202
Robert Edward Farrell officer: CFO BIOVEST INTERNATIONAL, INC., 300 S HYDE PARK AVENUE, SUITE 210, TAMPA FL 33606
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568